The latest news and views from bridge therapeutics

02/27/18 Is Abuse of a Nerve Pain Drug On the Rise? FDA Intends to Find Out

Greg Sullivan, MD, Chief Scientific Officer and CEO of Bridge Therapeutics, was recently interviewed by Bronwyn Mixter of Bloomberg BNA about the abuse of gabapentinoid pain drugs. Dr. Sullivan explains how buprenorphine is a safe alternative for many of the dangerous drugs that are currently prescribed for chronic pain.

February 27, 2018

In the article Dr. Sullivan discusses the advantages of Buprenorphine compared to other opioids “buprenorphine was originally developed as a pain drug in the 1970s. Patients who take the drug don’t have euphoria, and it has no sedation and overdose risks” he said. He also went on to recommend “If patients need to stay on a pain drug for more than the standard two weeks when pain becomes chronic, they could switch to buprenorphine and get pain relief without the problems of tolerance, dependence, and lack of pain control” Sullivan said.

Bloomberg BNA is an affiliate of Bloomberg L.P., the global business, financial information and news leader.

Read the full article here

02/21/18 Pharmaceutical Startup, Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as New Chief Operating Officer

The innovative late development-stage pharmaceutical startup, Bridge Therapeutics, has named David H. Bergstrom, Ph.D. as its new Chief Operating Officer effective immediately.

February 21, 2018

Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has overseen and been intimately involved in moving new products from the research phase to eventual successful commercial production. He has also launched products across numerous therapeutic areas and dosage form delivery technologies.

Dr. Bergstrom earned his Ph.D., M.S. and B.S. degrees in Pharmaceutics, Pharmaceutical Chemistry and Pharmacy from the University of Utah, The University of Michigan and Ferris State University, respectively.

Read More

02/20/18 Eight Ways Doctors Can Address The Opioid Epidemic

Managed Healthcare Executive Discusses How Doctors Can Address The Opioid Epidemic

Managed Healthcare Executive published a story in January that gave medical doctors advice on how they can better address the opioid epidemic.

The publication turned to the Chief Scientific Officer of Bridge Therapeutics, Greg Sullivan M.D., and other medical experts for their feature, Eight ways doctors can address the opioid epidemic.

Dr. Sullivan, told the publication why it’s important for providers to have an exit strategy. “These patients find it difficult to wean from those medications after an illness or surgical episode has resolved, and they are unable to get off the medications because of withdrawal or other dependence issues,” Dr. Sullivan said. “Providers should have a definite exit strategy that involves weaning patients off of pain medications to less addicting agents early on, to help with the process of returning the patient to a normal livelihood without the need for chronic opiates.”

Dr. Sullivan also discussed why it’s best to pick a single physician when it comes to pain medication.

Read the full article here

12/07/17 Let’s fix the cause, rather than the problem, of opioid addiction

A recent article published on the website The Hill discusses the problem of prescribing addictive schedule III drugs for pain relief rather than the equally effective and non-addictive schedule II drugs, see full article here.


05/19/17 Fourteen things Trump needs to know about opioids

As President Trump promises to fight the opioid epidemic, here are 14 things experts want him to know

May 11, 2017

Greg Sullivan, MD, Chief Scientific Officer & CEO of Bridge Therapeutics, recently spoke with Managed Healthcare Executive for a special report entitled, “Fourteen things Trump needs to know about opioids.” Managed Healthcare Executive is read by 40,000 C-suite executives across the country at health plans and pharmacy benefit managers (PBMs).

Dr. Sullivan discussed with Managed Healthcare Executive managing editor Tracey Walker how the lack of non-addictive medications for long-term pain has left the 25 million chronic pain patients with no safe options to treat their condition, which means many of them are addicted to dangerous forms of opioids. “The tolerance that develops from traditional opioids reduces the analgesic effects of the medication, causing the patient to require a higher dose to achieve the same level of pain relief,” Dr. Sullivan said. “Compared with traditional full agonist opioids, buprenorphine affects the receptors in the brain responsible for euphoria to a lesser degree, decreasing the potential for addiction.”

He added: “Of all the opioids that have been approved for chronic pain, only buprenorphine has been demonstrated to be safe for long-term use, while not causing tolerance. It’s important to note that buprenorphine is effective in treating certain types of pain, but not inflammatory pain—it must be used in conjunction with an NSAID to effectively treat chronic pain.”

Read the full article here

05/19/17 Bridge Therapeutics to Present at BioTrinity 2017 Conference in London

CEO Dr. Greg Sullivan to introduce Bridge and its investigational drug BT-205 to investors and industry executives

May 10, 2017

(PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference and the largest of its type in the UK. The conference, in its 11th year, draws attendees from approximately 30 countries and includes more than 1,000 delegates, dozens of exhibitors, and industry leaders from investment firms and global pharma.

Dr. Sullivan’s presentation to key investors and senior industry executives focused on the story of Bridge Therapeutics and its investigational drug compound BT-205, a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation.

Read more


For more information about Bridge Therapeutics please contact us today using the form below.